

## Supplementary results of the experiments

**Table S2.** Overview of the medians, interquartile ranges (IQR) and the number of experiments (n) testing the percentages of non-living PMN

Percentage of non-living PMN	Median	IQR	n
cPMN without ARDS	0.2	0.2	36
cPMN with ARDS	0.4	0.5	29
tPMN without ARDS	36	32	32
tPMN with ARDS	20	38	30

**Table S3.** Overview of medians, interquartile ranges IQR, the number of trials n and the significance p of MFI(CD11b).

MFI(CD11b)	Median	IQR	n
cPMN without ARDS	337	288	12
cPMN with ARDS	416	633	10
tPMN without ARDS	332	1298	12
tPMN with ARDS	666	1022	9

**Table S4.** Overview of mean values (MV), standard deviation (SD), number of trials (n) and significance p of MFI(CD66b)

AFU (CD66b)	MV	SD	n
cPMN without ARDS	110	25	12
cPMN with ARDS	194	69	10
tPMN without ARDS	424	305	12
tPMN with ARDS	505	329	9

**Table S5.** Overview of mean values (MV), standard deviation (SD), number of trials (n) and significance p of MFI(CD62L)

AFU (CD62L)	MV	SD	n
cPMN without ARDS	170.3	19.6	11
cPMN with ARDS	72.6	14.9	8
tPMN without ARDS	44.6	26.0	12
tPMN with ARDS	44.7	26.1	10

**Table S6.** Overview of medians, interquartile ranges (IQR) and number of trials (n) of MFI(LOX-1).

AFU(LOX-1)	Median	IQR	n
cPMN without ARDS	7.9	3.0	11
cPMN with ARDS	9.7	9.3	9
tPMN without ARDS	203.4	835.4	12
tPMN with ARDS	235.0	561.3	9

**Table S7.** Overview of mean values (MV), standard deviation (SD), number of trials (n) and significance p of MFI(CD49d)

AFU (CD49d)	MV	SD	n
cPMN without ARDS	15.2	8.8	12
cPMN with ARDS	13.8	7.1	8
tPMN without ARDS	54.8	30.0	12
tPMN with ARDS	12.6	7.4	7

**Table S8.** Overview of mean values (MV), standard deviation (SD), number of trials (n) and significance p of MFI(CD29).

AFU (CD29)	MV	SD	n
cPMN without ARDS	15.0	4.9	12
cPMN with ARDS	14.5	10.4	9
tPMN without ARDS	53.2	42.3	11
tPMN with ARDS	20.2	15.1	9

**Table S9.** Overview of medians, interquartile ranges (IQR) and number of trials (n) of MFI(fMLP-R).

MFI (fMLP-R)	Median	IQR	n
cPMN without ARDS	26,4	22,8	13
cPMN with ARDS	34,4	19,7	9
tPMN without ARDS	389,1	1442,7	11
tPMN with ARDS	448,0	1591,9	9

**Table S10.** Overview of medians, interquartile ranges (IQR) and number of trials (n) of blank value MFI(DHR).

Blank value MFI(DHR)	Median	IQR	n
cPMN without ARDS	3,2	2,6	12
cPMN with ARDS	3,5	1,5	9
tPMN without ARDS	15,8	59,6	11
tPMN with ARDS	14,6	35,9	9

**Table S11.** Overview of medians, interquartile ranges (IQR) and number of trials (n) of blank value MFI(DHR) -fMLP+TNF  $\alpha$

MFI(DHR)-FMLP + TNF $\alpha$	Median	IQR	n
cPMN without ARDS	42	16	12
cPMN with ARDS	30	36	10
tPMN without ARDS	15	31	11
tPMN with ARDS	15	17	9

**Table S12.** Overview of medians, interquartile ranges (IQR) and number of trials (n) of blank value MFI(DHR)-PMA.

MFI(DHR)-PMA	Median	IQR	n
cPMN without ARDS	410	1064	13
cPMN with ARDS	403	547	9
tPMN without ARDS	138	303	12
tPMN with ARDS	45	146	10

## Supplement

### Measurement details of the flow cytometry

**Table S13.** Fluorescent dyes of the antibodies used, their channels and laser wavelengths.

Antibody	Coupled dye	Fluorescence channel (H = Height)	Absorption	Emission
CD11b	PE	FL2-H	488 nm	575 nm
CD62L	FITC	FL1-H	488 nm	525 nm
CD66b	APC	FL4-H	633 nm	660 nm
LOX-1	APC	FL4-H	633 nm	660 nm
CD49d	PE	FL2-H	488 nm	575 nm
CD29	FITC	FL1-H	488 nm	525 nm
FMLP-Receptor	APC	FL4-H	633 nm	660 nm

**Table S14.** Channels and wavelengths of the lasers of the substances used in the ROS experiment.

ROS experiment	Fluorescence channel (H = Height)	Absorption	Emission
Propidiumiodide	FL3-H	535 nm	617 nm
Rhodamine-123	FL1-H	508 nm	528 nm